Clinical Trials Logo

Angiomyolipoma clinical trials

View clinical trials related to Angiomyolipoma.

Filter by:

NCT ID: NCT01217125 Completed - Angiomyolipoma Clinical Trials

Rapamycin In Angiomyolipomas In Patients With Tuberous Sclerosis

Start date: October 2008
Phase: Phase 4
Study type: Interventional

The purpose of this study is to determine whether rapamycin is safe and effective in the treatment of renal angiomyolipomas in patients with tuberousclerosis.

NCT ID: NCT00792766 Completed - Tuberous Sclerosis Clinical Trials

Long Term Follow Up for RAD001 Therapy of Angiomyolipomata in Patients With Tuberous Sclerosis (TSC) and Sporadic Lymphangioleiomyomatosis (LAM)

Start date: December 2008
Phase: Phase 1/Phase 2
Study type: Interventional

This is an open label long term follow up study, open to those subjects who were previously enrolled in"RAD001 Therapy of Angiomyolipomata in Patients with Tuberous Sclerosis Complex and Sporadic Lymphangioleiomyomatosis", CCHMC IRB #2008-0812 and who meet the criteria for this long-term follow-up study. The hypothesis is that the drug will inhibit the growth of the angiomyolipomas and possibly even cause regression.

NCT ID: NCT00790400 Completed - Clinical trials for Lymphangioleiomyomatosis (LAM)

Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM)

EXIST-2
Start date: April 2009
Phase: Phase 3
Study type: Interventional

This study will evaluate the safety and efficacy of RAD001 in treating patients with Angiomyolipoma associated with Tuberous Sclerosis Complex or Sporadic Lymphangioleiomyomatosis.

NCT ID: NCT00457964 Completed - Tuberous Sclerosis Clinical Trials

RAD001 Therapy of Angiomyolipomata in Patients With TS Complex and Sporadic LAM

Start date: August 2005
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this research study is to find out what effects RAD001 has on angiomyolipomas of a person with Tuberous Sclerosis Complex and to determine the safe dose of RAD001 without toxicity. The hypothesis is that the drug will inhibit the growth of the angiomyolipomas and possibly even cause regression.

NCT ID: NCT00126672 Completed - Tuberous Sclerosis Clinical Trials

RAPAMYCIN FOR KIDNEY ANGIOMYOLIPOMAS

Start date: December 20, 2005
Phase: Phase 2
Study type: Interventional

This research study is evaluating a drug called rapamycin as a possible treatment for the lumps (or tumors) that form in the kidneys, called angiomyolipomas, in people who have either TSC or LAM. Kidney angiomyolipomas are tumors that are made up of blood vessels, muscle and fat. Rapamycin has been approved to treat other diseases, but it is investigational for treating kidney angiomyolipomas. Investigational means that it is being as a possible treatment for kidney angiomyolipomas but is not currently approved by the U.S. Food and Drug Administration (FDA) for treating this disease.